LONDON – Shield Therapeutics Ltd. reported positive data from the pivotal Phase III trial of ST10, an oral ferric iron replacement therapy, saying the results demonstrate the product could replace the need to administer intravenous iron in patients with anemia caused by inflammatory bowel disease (IBD).